Lysinuric protein intolerance
Lysinuric protein intolerance (LPI) is a rare inherited metabolic disorder characterized by an inability of the body to properly digest certain protein building blocks (amino acids), specifically lysine, arginine, and ornithine. This condition is classified as a urea cycle disorder because it can lead to an excess of ammonia in the bloodstream (hyperammonemia) due to the body's inability to effectively remove waste products of protein metabolism.
Signs and Symptoms[edit | edit source]
The signs and symptoms of LPI typically become apparent after an infant is weaned and starts to consume more protein from the diet. These can include failure to thrive, muscle weakness (hypotonia), and developmental delay. Some affected individuals may have episodes of confusion or coma due to hyperammonemia, especially after consuming a protein-rich meal.
Causes[edit | edit source]
LPI is caused by mutations in the SLC7A7 gene. This gene provides instructions for making a protein that is involved in the transport of certain amino acids across cell membranes. Mutations in the SLC7A7 gene disrupt the normal function of this protein, leading to the characteristic features of LPI.
Diagnosis[edit | edit source]
Diagnosis of LPI is based on the clinical symptoms, biochemical analysis of blood and urine, and confirmed by genetic testing. The biochemical analysis typically shows increased levels of lysine, arginine, and ornithine in the urine.
Treatment[edit | edit source]
There is currently no cure for LPI. Treatment is aimed at managing the symptoms and preventing complications. This may include a low-protein diet, supplementation with citrulline or arginine, and medications to prevent or control hyperammonemia.
Prognosis[edit | edit source]
The prognosis for individuals with LPI varies. Some individuals have a normal lifespan with good quality of life, while others may have severe complications such as lung disease or kidney failure.
See also[edit | edit source]
| Lysinuric protein intolerance Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
